Wanyi Zhang, Jiao Yan, Wen Huang, Bin Xu, Xuefei Wang, Lan Jiang, Liuyin Zhou
Department of Neurology, Chongqing Emergency Medical Center, Chongging University Central Hospital, Chongqing, China.
Department of Nursing, Chongqing Emergency Medical Center, Chongging University Central Hospital, Chongqing, China.
Front Neurol. 2024 May 24;15:1407241. doi: 10.3389/fneur.2024.1407241. eCollection 2024.
Parkinson's disease (PD) and inflammatory bowel disease (IBD) are the two chronic inflammatory diseases that are increasingly affecting millions of people worldwide, posing a major challenge to public health. PD and IBD show similarities in epidemiology, genetics, immune response, and gut microbiota. Here, we review the pathophysiology of these two diseases, including genetic factors, immune system imbalance, changes in gut microbial composition, and the effects of microbial metabolites (especially short-chain fatty acids). We elaborate on the gut-brain axis, focusing on role of gut microbiota in the pathogenesis of PD and IBD. In addition, we discuss several therapeutic strategies, including drug therapy, fecal microbiota transplantation, and probiotic supplementation, and their potential benefits in regulating intestinal microecology and relieving disease symptoms. Our analysis will provide a new understanding and scientific basis for the development of more effective therapeutic strategies for these diseases.
帕金森病(PD)和炎症性肠病(IBD)是两种慢性炎症性疾病,它们正日益影响着全球数百万人,对公共卫生构成重大挑战。帕金森病和炎症性肠病在流行病学、遗传学、免疫反应和肠道微生物群方面表现出相似性。在此,我们综述这两种疾病的病理生理学,包括遗传因素、免疫系统失衡、肠道微生物组成的变化以及微生物代谢产物(尤其是短链脂肪酸)的影响。我们详细阐述了肠-脑轴,重点关注肠道微生物群在帕金森病和炎症性肠病发病机制中的作用。此外,我们讨论了几种治疗策略,包括药物治疗、粪便微生物群移植和益生菌补充,以及它们在调节肠道微生态和缓解疾病症状方面的潜在益处。我们的分析将为开发针对这些疾病更有效的治疗策略提供新的认识和科学依据。